<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000827.v3.p1" parentStudy="phs000827.v3.p1" createDate="2016-09-01" modDate="2016-09-01">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>James P. Evans, MD, PhD</td><td>University of North Carolina, Chapel Hill, NC, USA</td></tr>
		<tr><td>Funding Source</td><td>U01 HG006487</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>N.C. Clinical Genomic Evaluation by NextGen Exome Sequencing (NCGENES)</StudyNameEntrez>
	<StudyNameReportPage>North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing (NCGENES)</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>North Carolina Clinical Genomic Evaluation by Next-generation Exome Sequencing</p> <p>This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. Participants are patients who were either seen in the UNC Cancer and Adult Genetics Clinic or referred to the study by their physician. They will be approached by their physician or a genetic counselor for recruitment. Once enrolled, a clinical geneticist or genetic counselor will obtain consent and collect blood samples to be analyzed using WES. Results may include information related to a diagnosis and incidental information. Medically actionable incidental findings will be CLIA-certified and returned to participants in a routine genetic counseling session, along with diagnostic findings. Eligible adult participants will be randomized to have the opportunity to choose to get certain types of non-medically actionable incidental findings, as well. Their decisions will be investigated, as will psychosocial and behavioral responses to sequencing and receiving sequencing information. This is a longitudinal, mixed methods study (i.e., multiple assessments pre- and post-return of results, with both quantitative and qualitative methods used to gather data). Because only the quantitative component of the study uses randomization, only measures and procedures associated with that component are included here. </p> <p>The third study release includes data of additional n=189 subjects.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Study participants represent different clinical phenotypes in which delineation of the molecular etiology might be amenable to genome-scale sequencing. The major areas include: <ul> <li>Hereditary cancer predisposition</li> <li>Neurological disorders (e.g. neuropathy, myopathy, movement disorders, epilepsy)</li> <li>Intellectual disability and dysmorphology/birth defects</li> <li>Cardiovascular conditions (e.g. Long QT syndrome, cardiomyopathy, thoracic aortic aneurysm and dissection)</li> <li>Retinal disorders</li> <li>Thrombotic disorders</li> </ul> </p> <p> Eligible patients should have certain hallmarks - including but not limited to, age of onset, severity, family history, or constellation of phenotypic features - suggestive of a monogenic etiology for their presenting signs or symptoms.</p> Excluded: <br/>Those with low suspicion of a hereditable disorder.]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Genetic Diseases, Inborn"/>
		<Disease vocab_source="MESH" vocab_term="Neoplasms"/>
		<Disease vocab_source="MESH" vocab_term="Adenomatous Polyposis Coli"/>
		<Disease vocab_source="MESH" vocab_term="Microcephaly"/>
		<Disease vocab_source="MESH" vocab_term="Aortic Aneurysm, Thoracic"/>
		<Disease vocab_source="MESH" vocab_term="Peripheral Nervous System Diseases"/>
		<Disease vocab_source="MESH" vocab_term="Cardiomyopathies"/>
		<Disease vocab_source="MESH" vocab_term="Leukodystrophy, Globoid Cell"/>
		<Disease vocab_source="MESH" vocab_term="Seizures"/>
		<Disease vocab_source="MESH" vocab_term="Mitochondria"/>
		<Disease vocab_source="MESH" vocab_term="Inflammation"/>
		<Disease vocab_source="MESH" vocab_term="Autoimmune Diseases"/>
		<Disease vocab_source="MESH" vocab_term="Progeria"/>
		<Disease vocab_source="MESH" vocab_term="Retina"/>
		<Disease vocab_source="MESH" vocab_term="Muscular Diseases"/>
		<Disease vocab_source="MESH" vocab_term="Rhabdomyolysis"/>
		<Disease vocab_source="MESH" vocab_term="Arrhythmias, Cardiac"/>
		<Disease vocab_source="MESH" vocab_term="Osteochondrodysplasias"/>
		<Disease vocab_source="MESH" vocab_term="Intellectual disability"/>
		<Disease vocab_source="MESH" vocab_term="Autistic Disorder"/>
		<Disease vocab_source="MESH" vocab_term="Neuromuscular Diseases"/>
		<Disease vocab_source="MESH" vocab_term="Paraplegia"/>
		<Disease vocab_source="MESH" vocab_term="Central Nervous System Diseases"/>
		<Disease vocab_source="MESH" vocab_term="Cholestasis"/>
		<Disease vocab_source="MESH" vocab_term="Anemia"/>
		<Disease vocab_source="MESH" vocab_term="Genetic Testing"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>James P. Evans, MD, PhD</AttName>
			<Institution>University of North Carolina, Chapel Hill, NC, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U01 HG006487</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="CSER-Consortium" url="https://cser-consortium.org"/>
		<Url name="NC GENES" url="http://www.med.unc.edu/ncgenes"/>
	</StudyURLs>
	<StudyHistory><![CDATA[
<p>2012 - March: First participant visit</p> <p>2012 - June: First participant&#39;s whole exome sequenced</p> <p>2012 - July: First participant variants analyzed by Molecular Analyst</p> <p>2012 - September: First participant genetic results independently verified and diagnosed</p> <p>2013 - January: First Results Discussion visit with participant</p> <p>2013 - January: First participant randomized in/out of study</p> <p>2013 - February: First implementation of independent participant ID Check system</p> <p>2013 - February: First implementation of independent participant ID Check system</p> <p>2013 - April: First participant report auto-generated</p> <p>2013 - June: First additional incidental analysis available</p> <p>2013 - August: First additional incidental analysis requested</p> <p>2014 - February: First incidental analysis results returned</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHGRI</DacName>
      <DacFullName>National Human Genome Research Institute</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000827.v3.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000827.v3.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000827.v3.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
